Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects

Richard C. Veith, Nancy Lewis, Janis I. Langohr, M. Michele Murburg, E. Alexandra Ashleigh, Sonia Castillo, Elaine R. Peskind, Marcella Pascualy, Garth Bissette, Charles Nemeroff, Murray A. Raskind

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

To assess the effect of desipramine (DMI) on corticotropin-releasing-factor (CRF) activity in the central nervous system, we measured cerebrospinal fluid (CSF) concentrations of CRF in healthy volunteers following short-term administration of DMI or placebo. DMI administration for 2 days was associated with a significant dose-related reduction in CRF concentrations. There was a nonsignificant 6% reduction in CRF concentrations among the 10 subjects who received 50 mg DMI (△ CRF: -3±2 pg/ml) and a significant 14% fall in the CRF concentrations of the eight subjects who received 100 mg DMI (△ CRF: -8±3 pg/ml). The mean CSF concentration of CRF was unchanged in the six subjects randomized to placebo (△ CRF: 1±5 pg/ml). DMI administration had no effect on CSF norepinephrine concentrations (n = 24) or on plasma cortisol (n = 25). We conclude that short-term administration of DMI in healthy volunteers is associated with a dose-related reduction in CSF concentrations of CRF.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalPsychiatry Research
Volume46
Issue number1
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Desipramine
Corticotropin-Releasing Hormone
Cerebrospinal Fluid
Healthy Volunteers
Placebos
Hydrocortisone
Norepinephrine
Central Nervous System

Keywords

  • cortisol
  • hypothalamic-pituitary-adrenal axis
  • Norepinephrine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Veith, R. C., Lewis, N., Langohr, J. I., Murburg, M. M., Ashleigh, E. A., Castillo, S., ... Raskind, M. A. (1993). Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Research, 46(1), 1-8. https://doi.org/10.1016/0165-1781(93)90002-X

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. / Veith, Richard C.; Lewis, Nancy; Langohr, Janis I.; Murburg, M. Michele; Ashleigh, E. Alexandra; Castillo, Sonia; Peskind, Elaine R.; Pascualy, Marcella; Bissette, Garth; Nemeroff, Charles; Raskind, Murray A.

In: Psychiatry Research, Vol. 46, No. 1, 01.01.1993, p. 1-8.

Research output: Contribution to journalArticle

Veith, RC, Lewis, N, Langohr, JI, Murburg, MM, Ashleigh, EA, Castillo, S, Peskind, ER, Pascualy, M, Bissette, G, Nemeroff, C & Raskind, MA 1993, 'Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects', Psychiatry Research, vol. 46, no. 1, pp. 1-8. https://doi.org/10.1016/0165-1781(93)90002-X
Veith, Richard C. ; Lewis, Nancy ; Langohr, Janis I. ; Murburg, M. Michele ; Ashleigh, E. Alexandra ; Castillo, Sonia ; Peskind, Elaine R. ; Pascualy, Marcella ; Bissette, Garth ; Nemeroff, Charles ; Raskind, Murray A. / Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. In: Psychiatry Research. 1993 ; Vol. 46, No. 1. pp. 1-8.
@article{8894e67a243d44198e6a3f1dd655c07b,
title = "Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects",
abstract = "To assess the effect of desipramine (DMI) on corticotropin-releasing-factor (CRF) activity in the central nervous system, we measured cerebrospinal fluid (CSF) concentrations of CRF in healthy volunteers following short-term administration of DMI or placebo. DMI administration for 2 days was associated with a significant dose-related reduction in CRF concentrations. There was a nonsignificant 6{\%} reduction in CRF concentrations among the 10 subjects who received 50 mg DMI (△ CRF: -3±2 pg/ml) and a significant 14{\%} fall in the CRF concentrations of the eight subjects who received 100 mg DMI (△ CRF: -8±3 pg/ml). The mean CSF concentration of CRF was unchanged in the six subjects randomized to placebo (△ CRF: 1±5 pg/ml). DMI administration had no effect on CSF norepinephrine concentrations (n = 24) or on plasma cortisol (n = 25). We conclude that short-term administration of DMI in healthy volunteers is associated with a dose-related reduction in CSF concentrations of CRF.",
keywords = "cortisol, hypothalamic-pituitary-adrenal axis, Norepinephrine",
author = "Veith, {Richard C.} and Nancy Lewis and Langohr, {Janis I.} and Murburg, {M. Michele} and Ashleigh, {E. Alexandra} and Sonia Castillo and Peskind, {Elaine R.} and Marcella Pascualy and Garth Bissette and Charles Nemeroff and Raskind, {Murray A.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/0165-1781(93)90002-X",
language = "English",
volume = "46",
pages = "1--8",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects

AU - Veith, Richard C.

AU - Lewis, Nancy

AU - Langohr, Janis I.

AU - Murburg, M. Michele

AU - Ashleigh, E. Alexandra

AU - Castillo, Sonia

AU - Peskind, Elaine R.

AU - Pascualy, Marcella

AU - Bissette, Garth

AU - Nemeroff, Charles

AU - Raskind, Murray A.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - To assess the effect of desipramine (DMI) on corticotropin-releasing-factor (CRF) activity in the central nervous system, we measured cerebrospinal fluid (CSF) concentrations of CRF in healthy volunteers following short-term administration of DMI or placebo. DMI administration for 2 days was associated with a significant dose-related reduction in CRF concentrations. There was a nonsignificant 6% reduction in CRF concentrations among the 10 subjects who received 50 mg DMI (△ CRF: -3±2 pg/ml) and a significant 14% fall in the CRF concentrations of the eight subjects who received 100 mg DMI (△ CRF: -8±3 pg/ml). The mean CSF concentration of CRF was unchanged in the six subjects randomized to placebo (△ CRF: 1±5 pg/ml). DMI administration had no effect on CSF norepinephrine concentrations (n = 24) or on plasma cortisol (n = 25). We conclude that short-term administration of DMI in healthy volunteers is associated with a dose-related reduction in CSF concentrations of CRF.

AB - To assess the effect of desipramine (DMI) on corticotropin-releasing-factor (CRF) activity in the central nervous system, we measured cerebrospinal fluid (CSF) concentrations of CRF in healthy volunteers following short-term administration of DMI or placebo. DMI administration for 2 days was associated with a significant dose-related reduction in CRF concentrations. There was a nonsignificant 6% reduction in CRF concentrations among the 10 subjects who received 50 mg DMI (△ CRF: -3±2 pg/ml) and a significant 14% fall in the CRF concentrations of the eight subjects who received 100 mg DMI (△ CRF: -8±3 pg/ml). The mean CSF concentration of CRF was unchanged in the six subjects randomized to placebo (△ CRF: 1±5 pg/ml). DMI administration had no effect on CSF norepinephrine concentrations (n = 24) or on plasma cortisol (n = 25). We conclude that short-term administration of DMI in healthy volunteers is associated with a dose-related reduction in CSF concentrations of CRF.

KW - cortisol

KW - hypothalamic-pituitary-adrenal axis

KW - Norepinephrine

UR - http://www.scopus.com/inward/record.url?scp=0027536051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027536051&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(93)90002-X

DO - 10.1016/0165-1781(93)90002-X

M3 - Article

C2 - 8464952

AN - SCOPUS:0027536051

VL - 46

SP - 1

EP - 8

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -